Please login to the form below

Not currently logged in
Email:
Password:

Keynote-024

This page shows the latest Keynote-024 news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

In recently published long-term data from the phase 3 KEYNOTE-024 trial, Keytruda reduced the risk of death by 38% versus chemotherapy at the five-year time point among NSCLC ... In addition, another advanced, PD-1-positive NSCLC monotherapy study of

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...